2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 644

Association of Osteonectin, Osteopontin and Osteocalcin with Inflammation and Cardiovascular Risk in Patients with Axial Spondyloarthritis
Abstract Number: 645

An Oral Tyk2 Inhibitor Effectively Suppresses the Development of Murine Th17 Cells In Vivo and Prevents Joint Damage in Experimental Ankylosing Spondylitis
Abstract Number: 646

Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Is a Susceptibility Factor for Early Axial Spa Meeting the ASAS Classification Criteria: Results from the Spondyloarthritis Caught Early and DEvenir des Spondyloarthrites Indifférenciées Récentes Cohorts
Abstract Number: 647

Gene Expression in Cellular Subsets in Psoriatic Disease
Abstract Number: 648

Are Choline Metabolites Associated with Inflammation in Psoriatic Arthritis?
Abstract Number: 649

Role of Eicosanoids As Biomarkers in Psoriatic Arthritis
Abstract Number: 650

Genome-Wide DNA Methylation, Transcriptomics, and Proteomics of Psoriasis and Psoriatic Arthritis in Monozygotic Twins
Abstract Number: 651

Role of Mir-21-5p As a Potential Biomarker of Psoriatic Arthritis and Response to Treatment
Abstract Number: 652

Investigating the Role of Mechanical Stress in Spondyloarthritis Pathogenesis
Abstract Number: 653

Reduced Ubiquitination of Misfolded HLA-B27 Is Associated with Inefficient Degradation By ERAD and Autophagy
Abstract Number: 654

Effect of Anti Tnfα Drugs on the Frequency of Circulating CD19+CD24hiCD38hi Breg Cells in Ankylosing Spondylitis
Abstract Number: 655

Innate Lymphoid Cells – New Players in Psoriatic Arthritis
Abstract Number: 656

Prostaglandin E2 and Its Receptor Subtype EP4 Are Involved in Ankylosing Spondylitis Disease Progression
Abstract Number: 657

Dyslipidemia Management Is Insufficient in Psoriatic Arthritis Despite Increased Cardiovascular Morbidity and Mortality
Abstract Number: 658

Functionally Active MAIT Cells in Psoriatic Arthritis: A New Member of the IL-23/IL-17 Cytokine Network

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].